Clinical Trials Logo

Filter by:
NCT ID: NCT02877030 Completed - HTLV-1 Clinical Trials

Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus

Start date: April 2, 2017
Phase: N/A
Study type: Interventional

Testing the effectiveness of an exercise protocol engines sensory performed through a virtual reality platform in individuals infected with HTLV-1

NCT ID: NCT02876835 Completed - Anaemia Clinical Trials

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Start date: September 27, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

NCT ID: NCT02875873 Completed - Critical Illness Clinical Trials

Balanced Solution Versus Saline in Intensive Care Study

BaSICS
Start date: May 27, 2017
Phase: Phase 3
Study type: Interventional

A 2x2 factorial randomized study to evaluate the effect of a balanced crystalloid solution compared with 0.9% saline, and of rapid vs. slow infusion on clinical outcomes of critically ill patients

NCT ID: NCT02874976 Completed - Clinical trials for Excessive Physical Exercise, Unspecified

Phototherapy Applied in Combination With Aerobic Training

Start date: May 2016
Phase: N/A
Study type: Interventional

Interventional

NCT ID: NCT02873871 Completed - Clinical trials for Coronary Artery Disease With Myocardial Infarction

Comparison of 2 Hemostasis Techniques After Transradial Coronary

Start date: August 2015
Phase: N/A
Study type: Interventional

Randomized clinical trial to compare radial artery patency after transradial coronary catheterization using 2 different hemostasis techniques. Patients submitted to diagnostic or therapeutic coronary catheterization will be prospectively enrolled in this single-center trial and will be randomized to radial hemostasis with TerumoBand® or a standardized compressive dressing with gauze and elastic bandage.

NCT ID: NCT02872922 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effects of Low Intensity Therapeutic Ultrasound on Endothelial Function

Start date: December 10, 2016
Phase: N/A
Study type: Interventional

Endothelium is a cell layer that interposes blood and smooth muscle of vessels. This biological sensor reacts to physical and chemical stimuli by synthesis and/or liberation of regulatory substances like nitric oxide (NO), which acts on vascular tone, growth of muscle cells and platelet aggregation and leukocyte. Clinically, endothelial function measured by technique flow-mediated dilation (FMD) is a strong predictor of cardiovascular events and all-cause mortality. Previo study demonstrated that continuous and pulsed therapeutic 1-MHz ultrasound waveforms improved endothelial function in health volunteers and this vasodilation persisted for 20 min, which provided them with anti-inflammatory vascular effects. In subjects with type 2 diabetes (DM2) the chronical hyperglycemia and dyslipidemia reduce NO bioavailability causing endothelial dysfunction. Low intensity therapeutic ultrasound is an electrotherapeutic instrument employed in musculoskeletal injuries that promotes endothelium-dependent vasodilation, and its mechanism of action has not been studied on DM2. The aim of our study is evaluate endothelial function of patients with DM2 after different waveforms (placebo, continuous and pulsed) of therapeutic ultrasound. Therapeutic ultrasound is a electrotherapeutic instrument that can changes arterial endothelial function of subjects with DM2 because of NO bioavailability increasing, which implies anti-inflammatory and vasodilatory beneficial alterations for diabetic patients.

NCT ID: NCT02870257 Completed - Clinical trials for Shoulder Impingement Syndrome

Effects of Overload Progressive in the Treatment of Shoulder

Start date: August 2016
Phase: N/A
Study type: Interventional

Seventy subjects with shoulder impingement syndrome associated with scapular dyskinesis will be recruited and randomized into two groups of treatment. The group "a" will receive a strenghtening protocol with progressive overload during 20 sessions and group "b" will receive the same protocol with minimal load, without change during the 20 sessions. The primary outcomes measures will be pain, function, quality of life, global impression of recovery. The change will be measure from baseline at 10 weeks (after 20 sessions), 3 and 6 months (follow-up). The secundary outcomes will be disability, quality of life measure by other instruments, shoulder muscle strength and scapular 3d kinematic variables. For these data, change will be measure from baseline at 10 weeks (after 20 sessions).

NCT ID: NCT02869789 Completed - Lung Cancer Clinical Trials

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Start date: October 5, 2016
Phase: Phase 4
Study type: Interventional

A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

NCT ID: NCT02869139 Completed - Thirst Clinical Trials

Package of Mentholated Measures for the Relief of Thirst in the Anesthesia Recovery Room

Start date: April 2014
Phase: N/A
Study type: Interventional

Package of mentholated measures for the relief of thirst in the anesthesia recovery room: Randomized clinical trial

NCT ID: NCT02867020 Completed - Prostate Cancer Clinical Trials

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Start date: October 11, 2017
Phase: Phase 2
Study type: Interventional

Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced or metastatic prostate cancer which ADT was indicated.